MIRA PHARMACEUTICALS, INC.MIRAEarnings & Financial Report
MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on researching, developing, and commercializing novel prescription therapies for rare diseases and unmet medical needs. It primarily serves global patient populations, prioritizing therapeutic areas with limited existing treatment options to improve patient outcomes.
MIRA Q3 FY2025 Key Financial Metrics
Revenue
$15.7K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$-1.1M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
-7247.7%
YoY Growth
-58.4%
EPS
$-1.18
MIRA PHARMACEUTICALS, INC. Q3 FY2025 Financial Summary
MIRA PHARMACEUTICALS, INC. reported revenue of $15.7K (down 58.4% YoY) for Q3 FY2025, with a net profit of $-1.1M (up 44.3% YoY) (-7247.7% margin).
Key Financial Metrics
| Total Revenue | $15.7K |
|---|---|
| Net Profit | $-1.1M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
MIRA PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
MIRA PHARMACEUTICALS, INC. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $15.7K | -58.4% | $-1.1M | -7247.7% |
| Q3 FY2024 | $37.8K | — | $-2.0M | -5413.9% |
Income Statement
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Revenue | $37752 | $15697 |
| YoY Growth | N/A | -58.4% |
Balance Sheet
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Assets | $4.3M | $7.6M |
| Liabilities | $692833 | $83926 |
| Equity | $3.6M | $7.5M |
Cash Flow
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Operating CF | $-1.8M | $-1.1M |